Table 2 Primary treatment modalities and responses in patients with ENKTL
Characteristic | Total (cases) | Blood four-type group [cases (%)] | P | Blood two-type group [cases (%)] | P | ||||
|---|---|---|---|---|---|---|---|---|---|
O | A | B | AB | O | Non-O | ||||
Treatment modality | Â | Â | Â | Â | Â | 0.701 | Â | Â | 0.690 |
 CT combined RT | 436 | 164 (64.3) | 118 (60.5) | 120 (63.8) | 34 (57.6) |  | 164 (64.3) | 272 (61.5) |  |
 CT alone | 171 | 57 (22.4) | 49 (25.1) | 47 (25.0) | 18 (30.5) |  | 57 (22.4) | 114 (25.8) |  |
 RT alone | 72 | 26 (10.2) | 23 (11.8) | 16 (8.5) | 7 (11.9) |  | 26 (10.2) | 46 (10.4) |  |
 Best supportive care | 18 | 8 (3.1) | 5 (2.6) | 5 (2.7) | 0 (0) |  | 8 (3.1) | 10 (2.3) |  |
CT regimen | Â | Â | Â | Â | Â | 0.675 | Â | Â | 0.534 |
 CHOP or CHOP-like | 218 | 73 (28.6) | 68 (34.9) | 61 (32.4) | 16 (27.1) |  | 73 (28.6) | 145 (32.8) |  |
 EPOCH | 105 | 43 (16.9) | 24 (12.3) | 32 (17.0) | 6 (10.2) |  | 43 (16.9) | 62 (14.0) |  |
 ATT | 43 | 15 (5.9) | 13 (6.7) | 12 (6.4) | 3 (5.1) |  | 15 (5.9) | 28 (6.3) |  |
 GEMOX + L-asp | 232 | 85 (33.3) | 61 (31.3) | 60 (31.9) | 26 (44.1) |  | 85 (33.3) | 147 (33.3) |  |
 SMILE | 9 | 5 (2.0) | 1 (0.4) | 2 (1.1) | 1 (0.4) |  | 5 (2.0) | 4 (0.9) |  |
Complete response | 509 | 202 (79.2) | 133 (68.2) | 131 (69.7) | 43 (72.9) | 0.040 | 202 (79.2) | 307 (69.5) | 0.005 |